Study guide
3.3 IV Infusion Rates, Drop Factors, Osmolarity & Creatinine Clearance (Cockcroft-Gault)
PEBC Pharmacist Qualifying Examination Part I MCQ
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Canadian Pharmacy Regulatory Framework & Federal Legislation
1.1 Food and Drugs Act, Regulations, and Health Canada Oversight 1.2 Controlled Drugs and Substances Act (CDSA) & Controlled Substances Regulations (CSR) 1.3 NAPRA Drug Scheduling Framework & National Model Standards of Practice
2 Chapter 2: Ethics, Scope of Practice & Safety Culture
2.1 Professional Ethics, Fiduciary Duty & Health Information Privacy 2.2 Expanded Scope of Practice: Minor Ailments Prescribing, Renewals & Injections 2.3 Equity, Diversity, Inclusion, Cultural Safety & Continuous Quality Improvement
3 Chapter 3: Pharmaceutical Calculations & Posology
3.1 Concentrations, Dilutions, Alligations & Reconstitution 3.2 Dosing by Weight/BSA, Days Supply & Pediatric/Geriatric Dose Adjustments 3.3 IV Infusion Rates, Drop Factors, Osmolarity & Creatinine Clearance (Cockcroft-Gault)
4 Chapter 4: Compounding, Dispensing & Product Integrity
4.1 Non-Sterile Compounding & Beyond-Use Dating (NAPRA Standards) 4.2 Sterile Preparations & Hazardous Drug Handling (NAPRA / NIOSH Principles) 4.3 Prescription Verification, Auxiliary Labeling, Cold Chain & Medication Incident Prevention (ISMP Canada) 4.4 Dispensing Operations: Interchangeability, Adjudication, Compliance Packaging, Release & Inventory Control
5 Chapter 5: Clinical Pharmacology & Pharmacokinetics
5.1 Pharmacokinetic Principles: Clearance, Volume of Distribution, Half-life & Steady State 5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions 5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities
6 Chapter 6: Evidence-Based Medicine & Literature Appraisal
6.1 Study Designs, Bias & Levels of Evidence in Clinical Research 6.2 Biostatistics: ARR, RRR, NNT, NNH, Confidence Intervals & P-values 6.3 Applying Canadian Practice Guidelines to Clinical Decision-Making 6.4 Drug Information Practice, Diagnostic Test Accuracy & Pharmacoeconomics
7 Chapter 7: Cardiovascular Pharmacotherapy: Hypertension, Dyslipidemia & CAD
7.1 Hypertension Management (Hypertension Canada Guidelines, Targets & Regimens) 7.2 Dyslipidemia & Atherosclerotic Cardiovascular Disease (CCS Guidelines & Statin Therapy) 7.3 Ischemic Heart Disease & Acute Coronary Syndromes (Antiplatelet & Antianginal Therapy)
8 Chapter 8: Cardiovascular Pharmacotherapy: Heart Failure, Arrhythmias & Anticoagulation
8.1 Heart Failure with Reduced & Preserved Ejection Fraction (GDMT & Monitoring) 8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control 8.3 Venous Thromboembolism & Anticoagulation Therapy (DOACs, Warfarin & Thrombosis Canada)
9 Chapter 9: Endocrine & Metabolic Disorders
9.1 Type 2 Diabetes: Glycemic Targets, Non-Insulin Pharmacotherapy (Diabetes Canada) 9.2 Insulin Regimens, Type 1 Diabetes, Hypoglycemia & Diabetic Emergencies (DKA/HHS) 9.3 Thyroid Disorders & Osteoporosis (Diagnostic Parameters & Therapeutic Management)
10 Chapter 10: Respiratory & Gastrointestinal Disorders
10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers) 10.2 Chronic Obstructive Pulmonary Disease (COPD) & Inhaler Delivery Systems 10.3 Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease & GI Bleeding 10.4 Lower GI & Liver Disorders: Constipation, Diarrhea, IBS, IBD & Cirrhosis
11 Chapter 11: Infectious Diseases & Antimicrobial Stewardship
11.1 Respiratory Tract Infections: Otitis, Sinusitis, Pharyngitis, CAP & HAP 11.2 Urinary Tract, Skin/Soft Tissue & Sexually Transmitted Infections 11.3 Systemic Infections, Clostridioides difficile & Antimicrobial Stewardship Principles 11.4 HIV Prevention & Treatment, Viral Hepatitis, Tuberculosis & Fungal Infections
12 Chapter 12: Central Nervous System & Mental Health
12.1 Major Depressive Disorder & Anxiety Disorders (First-Line Agents & Safety) 12.2 Bipolar Disorder, Schizophrenia & Psychopharmacology Monitoring 12.3 Epilepsy, Seizure Types, Antiseizure Medications & Neuropathic Pain 12.4 Dementia, Parkinson Disease, Migraine, Insomnia & Restless Legs Syndrome
13 Chapter 13: Special Populations, Pain Management & Substance Use
13.1 Acute & Chronic Pain Management: Multimodal Analgesia & Opioid Stewardship 13.2 Substance Use Disorders: Opioid Agonist Therapy, Harm Reduction & Alcohol Withdrawal 13.3 Special Populations: Pharmacotherapy in Pregnancy, Lactation & Geriatrics (Deprescribing / Beers) 13.4 Palliative Care & Pediatric Pharmacotherapy
14 Chapter 14: Renal, Rheumatologic, Hematologic & Oncology Supportive Care
14.1 Chronic Kidney Disease, Acute Kidney Injury & Electrolyte Disorders 14.2 Osteoarthritis, Rheumatoid Arthritis & Gout 14.3 Anemias & Oncology Supportive Care
15 Chapter 15: Minor Ailments, Dermatology and Women's & Men's Health
15.1 Minor Ailments I: Allergic Rhinitis, Colds & Influenza, Eye and Ear Conditions 15.2 Minor Ailments II: Acne, Dermatitis, Psoriasis, Lice, Scabies & Sun Protection 15.3 Women's & Men's Health: Contraception, Emergency Contraception, Menopause, BPH, ED & Overactive Bladder
16 Chapter 16: Immunization & Health Promotion
16.1 Immunization Practice: NACI Recommendations, Administration, Cold Chain & Adverse Events 16.2 Health Promotion: Smoking Cessation, Weight Management, Screening & Social Determinants of Health
17 Chapter 17: Patient Care Process, Communication & Stewardship
17.1 The Patient Care Process: Assessment, Care Planning & Patient Interviewing 17.2 Patient Education, Device Counselling, Health Literacy & Overcoming Barriers 17.3 Interprofessional Collaboration, Pharmacy Workflow, Team Delegation & Drug Shortage Stewardship
3.3 IV Infusion Rates, Drop Factors, Osmolarity & Creatinine Clearance (Cockcroft-Gault)
Key Takeaways Explain This Topic AI
IV flow rates require distinct dimensional units: volumetric infusion pumps run in mL/hr, whereas gravity administration sets require drop rate calculations via Drip Rate (gtt/min) = Volume (mL) × Drop Factor (gtt/mL) Time (min) \text{Drip Rate (gtt/min)} = \frac{\text{Volume (mL)} \times \text{Drop Factor (gtt/mL)}}{\text{Time (min)}} Drip Rate (gtt/min) = Time (min) Volume (mL) × Drop Factor (gtt/mL) .
Standard IV tubing calibrations distinguish macrodrip sets (10, 15, or 20 gtt/mL for rapid adult infusions) from microdrip sets (60 gtt/mL), where flow rate in mL/hr is numerically identical to drop rate in gtt/min.
Electrolyte conversions link mass to ionic charge: milliequivalents represent chemical combining power ( mEq = mg × valence MW \text{mEq} = \frac{\text{mg} \times \text{valence}}{\text{MW}} mEq = MW mg × valence ) and millimoles represent molecular count ( mmol = mg MW \text{mmol} = \frac{\text{mg}}{\text{MW}} mmol = MW mg ); monovalent ions yield 1 mmol = 1 mEq 1\text{ mmol} = 1\text{ mEq} 1 mmol = 1 mEq , whereas divalent ions yield 1 mmol = 2 mEq 1\text{ mmol} = 2\text{ mEq} 1 mmol = 2 mEq .
Parenteral solutions with osmolarities exceeding 900 mOsmol/L must be infused through a central venous line to prevent chemical thrombophlebitis; isotonicity adjustments use the sodium chloride equivalent ( E E E -value) method.
Creatinine clearance estimation in Canadian SI units uses the Cockcroft-Gault formula from the PEBC formula sheet: CrCl (mL/min) = ( 140 − age ) × weight (kg) × 1.2 S cr ( μ mol/L ) \text{CrCl (mL/min)} = \frac{(140 - \text{age}) \times \text{weight (kg)} \times 1.2}{S_{\text{cr}}\ (\mu\text{mol/L})} CrCl (mL/min) = S cr ( μ mol/L ) ( 140 − age ) × weight (kg) × 1.2 , multiplied by 0.85 for females, with actual body weight unless the stem specifies IBW or AdjBW.
Last updated: October 2026
3.3 IV Infusion Rates, Drop Factors, Osmolarity & Creatinine Clearance (Cockcroft-Gault)
Intravenous (IV) pharmacotherapy demands absolute quantitative precision. Unlike oral administration, where absorption barriers and first-pass hepatic metabolism provide a temporary buffer, intravenous infusions deliver active drugs and electrolytes directly into systemic circulation. Pharmacists must compute infusion pump flow rates, gravity drop factors, electrolyte combining powers in milliequivalents and millimoles, solution osmolarities, and renal dose titrations using the Cockcroft-Gault creatinine clearance formula.
Intravenous Infusion Dynamics: Volumetric Rates & Gravity Drop Factors
Intravenous solutions are administered either through electronic volumetric infusion pumps calibrated in millilitres per hour ( mL/hr \text{mL/hr} mL/hr ) or via gravity infusion sets regulated in drops per minute ( gtt/min \text{gtt/min} gtt/min , from the Latin guttae ):
Volumetric Pump Rate Calculations
Flow Rate (mL/hr) = Total Volume to Infuse (mL) Infusion Duration (hours) \text{Flow Rate (mL/hr)} = \frac{\text{Total Volume to Infuse (mL)}}{\text{Infusion Duration (hours)}} Flow Rate (mL/hr) = Infusion Duration (hours) Total Volume to Infuse (mL)
If an IV piggyback of piperacillin/tazobactam in 100 mL 100\text{ mL} 100 mL of normal saline is ordered over 30 minutes: Flow Rate = 100 mL 0.5 hours = 200 mL/hr \text{Flow Rate} = \frac{100\text{ mL}}{0.5\text{ hours}} = 200\text{ mL/hr} Flow Rate = 0.5 hours 100 mL = 200 mL/hr
Gravity Drip Sets and Drop Factors
When electronic infusion pumps are unavailable, the drip rate is manually timed by counting drops falling into the IV administration set drip chamber. Tubing manufacturers engineer drip orifices to deliver a calibrated number of drops per millilitre, known as the drop factor ( gtt/mL \text{gtt/mL} gtt/mL ):
Drip Rate (gtt/min) = Infusion Volume (mL) × Drop Factor (gtt/mL) Infusion Duration (minutes) \text{Drip Rate (gtt/min)} = \frac{\text{Infusion Volume (mL)} \times \text{Drop Factor (gtt/mL)}}{\text{Infusion Duration (minutes)}} Drip Rate (gtt/min) = Infusion Duration (minutes) Infusion Volume (mL) × Drop Factor (gtt/mL)
Administration Set Type Calibrated Drop Factor Primary Clinical Indications
Macrodrip Sets 10 gtt/mL 10\text{ gtt/mL} 10 gtt/mL , 15 gtt/mL 15\text{ gtt/mL} 15 gtt/mL , or 20 gtt/mL 20\text{ gtt/mL} 20 gtt/mL Routine adult IV hydration, replacement fluid boluses, blood products
Microdrip (Minidrip) Sets 60 gtt/mL 60\text{ gtt/mL} 60 gtt/mL Pediatric infusions, neonatal medicine, low-rate critical care drug infusions
Note
The Microdrip Identity Shortcut : When using a standard 60 gtt/mL 60\text{ gtt/mL} 60 gtt/mL microdrip set, the flow rate in mL/hr \text{mL/hr} mL/hr is mathematically identical to the drip rate in gtt/min \text{gtt/min} gtt/min :
Drip Rate (gtt/min) = Rate (mL/hr) × 60 gtt/mL 60 min/hr = Rate (mL/hr) \text{Drip Rate (gtt/min)} = \frac{\text{Rate (mL/hr)} \times 60\text{ gtt/mL}}{60\text{ min/hr}} = \text{Rate (mL/hr)} Drip Rate (gtt/min) = 60 min/hr Rate (mL/hr) × 60 gtt/mL = Rate (mL/hr)
For instance, an infusion ordered at 25 mL/hr 25\text{ mL/hr} 25 mL/hr using microdrip tubing runs at exactly 25 gtt/min 25\text{ gtt/min} 25 gtt/min .
Electrolyte Posology: Milliequivalents, Millimoles, and Milligrams
Electrolyte concentrations are expressed in units of mass ( mg \text{mg} mg or g \text{g} g ), molecular count ( mmol \text{mmol} mmol ), or chemical combining power ( mEq \text{mEq} mEq ):
Mole / Millimole ( mmol \text{mmol} mmol ) : Represents molecular quantity. One millimole equals the formula weight of the substance in milligrams: mmol = Weight (mg) Molecular Weight (g/mol) \text{mmol} = \frac{\text{Weight (mg)}}{\text{Molecular Weight (g/mol)}} mmol = Molecular Weight (g/mol) Weight (mg)
Equivalent / Milliequivalent ( mEq \text{mEq} mEq ) : Represents the chemical combining activity of an ion, factoring in its electrical charge ( valence , z z z ): mEq = Weight (mg) × Valence Molecular Weight (g/mol) = mmol × Valence \text{mEq} = \frac{\text{Weight (mg)} \times \text{Valence}}{\text{Molecular Weight (g/mol)}} = \text{mmol} \times \text{Valence} mEq = Molecular Weight (g/mol) Weight (mg) × Valence = mmol × Valence
- Ion / Substance Chemical Symbol Valence ( z z z ) Atomic/Formula Weight (g/mol) Equivalent Weight (g/Eq)
- Sodium Na + \text{Na}^+ Na + 1 23.0 23.0
- Potassium K + \text{K}^+ K + 1 39.1 39.1
- Chloride Cl − \text{Cl}^- Cl − 1 35.5 35.5
- Bicarbonate HCO 3 − \text{HCO}_3^- HCO 3 − 1 61.0 61.0
- Calcium Ca 2 + \text{Ca}^{2+} Ca 2 + 2 40.1 20.05
- Magnesium Mg 2 + \text{Mg}^{2+} Mg 2 + 2 24.3 12.15
- Sulfate SO 4 2 − \text{SO}_4^{2-} SO 4 2 − 2 96.0 48.0
For univalent ions ( Na + , K + , Cl − , HCO 3 − \text{Na}^+, \text{K}^+, \text{Cl}^-, \text{HCO}_3^- Na + , K + , Cl − , HCO 3 − ), 1 mmol = 1 mEq 1\text{ mmol} = 1\text{ mEq} 1 mmol = 1 mEq . For divalent ions ( Ca 2 + , Mg 2 + \text{Ca}^{2+}, \text{Mg}^{2+} Ca 2 + , Mg 2 + ), 1 mmol = 2 mEq 1\text{ mmol} = 2\text{ mEq} 1 mmol = 2 mEq .
Clinical Distinction: Calcium Chloride vs. Calcium Gluconate
In Canadian hospital practice, confusion between calcium salts carries fatal risks:
Calcium Chloride Dihydrate ( CaCl 2 ⋅ 2 H 2 O \text{CaCl}_2 \cdot 2\text{H}_2\text{O} CaCl 2 ⋅ 2 H 2 O , MW = 147 g/mol \text{MW} = 147\text{ g/mol} MW = 147 g/mol , valence = 2): 1 g of CaCl 2 = 1 , 000 mg × 2 147 = 13.6 mEq of Ca 2 + = 273 mg of elemental Ca 1\text{ g of } \text{CaCl}_2 = \frac{1,000\text{ mg} \times 2}{147} = 13.6\text{ mEq of } \text{Ca}^{2+} = 273\text{ mg of elemental Ca} 1 g of CaCl 2 = 147 1 , 000 mg × 2 = 13.6 mEq of Ca 2 + = 273 mg of elemental Ca
Calcium Gluconate ( C 12 H 22 CaO 14 \text{C}_{12}\text{H}_{22}\text{CaO}_{14} C 12 H 22 CaO 14 , MW = 430.4 g/mol \text{MW} = 430.4\text{ g/mol} MW = 430.4 g/mol , valence = 2): 1 g of calcium gluconate = 1 , 000 mg × 2 430.4 = 4.65 mEq of Ca 2 + = 93 mg of elemental Ca 1\text{ g of calcium gluconate} = \frac{1,000\text{ mg} \times 2}{430.4} = 4.65\text{ mEq of } \text{Ca}^{2+} = 93\text{ mg of elemental Ca} 1 g of calcium gluconate = 430.4 1 , 000 mg × 2 = 4.65 mEq of Ca 2 + = 93 mg of elemental Ca
Calcium chloride provides nearly three times more elemental calcium per gram than calcium gluconate. Furthermore, calcium chloride causes severe tissue sloughing and necrosis if extravasated and must be given centrally or in life-threatening cardiac arrest; calcium gluconate is the standard choice for peripheral replacement.
Caution
Potassium Chloride (KCl) Infusion Safety : Intravenous potassium chloride must never be administered as an undiluted IV push (causes immediate fatal cardiac arrest). The maximum recommended peripheral IV concentration is 40 mEq/L 40\text{ mEq/L} 40 mEq/L , and the maximum peripheral infusion rate is 10 mEq/hr 10\text{ mEq/hr} 10 mEq/hr . Rates up to 20 mEq/hr 20\text{ mEq/hr} 20 mEq/hr mandate central venous access and continuous ECG telemetry monitoring.
- Parenteral Osmolarity, Tonicity & the Sodium Chloride Equivalent ( E E E -Value)
- Theoretical Osmolarity
Osmolarity expresses osmotic pressure as milliosmoles per litre of solution ( mOsmol/L \text{mOsmol/L} mOsmol/L ):
mOsmol/L = Weight of Solute (g/L) Molecular Weight (g/mol) × Number of Dissociated Particles × 1000 \text{mOsmol/L} = \frac{\text{Weight of Solute (g/L)}}{\text{Molecular Weight (g/mol)}} \times \text{Number of Dissociated Particles} \times 1000 mOsmol/L = Molecular Weight (g/mol) Weight of Solute (g/L) × Number of Dissociated Particles × 1000
Normal human serum osmolarity ranges from 275 to 295 mOsmol/kg 275\text{ to } 295\text{ mOsmol/kg} 275 to 295 mOsmol/kg .
Normal Saline ( 0.9 % w/v NaCl 0.9\%\text{ w/v } \text{NaCl} 0.9% w/v NaCl , MW = 58.5 \text{MW} = 58.5 MW = 58.5 , dissociates into 2 ions: Na + \text{Na}^+ Na + and Cl − \text{Cl}^- Cl − ): Osmolarity = 9 g/L 58.5 g/mol × 2 × 1000 = 307.7 mOsmol/L ≈ 308 mOsmol/L ( isotonic ) \text{Osmolarity} = \frac{9\text{ g/L}}{58.5\text{ g/mol}} \times 2 \times 1000 = 307.7\text{ mOsmol/L} \approx 308\text{ mOsmol/L} \quad (\text{isotonic}) Osmolarity = 58.5 g/mol 9 g/L × 2 × 1000 = 307.7 mOsmol/L ≈ 308 mOsmol/L ( isotonic )
Peripheral vs. Central Venous Access Threshold
Infusion of hypertonic solutions causes endothelial cell shrinkage, mechanical irritation, and chemical thrombophlebitis. In Canadian parenteral nutrition and intravenous standards, any peripheral IV solution must have an osmolarity ≤ 900 mOsmol/L \le 900\text{ mOsmol/L} ≤ 900 mOsmol/L . Formulations exceeding 900 mOsmol/L 900\text{ mOsmol/L} 900 mOsmol/L (e.g., concentrated total parenteral nutrition containing > 10 % >10\% > 10% dextrose or > 5 % >5\% > 5% amino acids) must be infused via a central venous line .
Tonicity Adjustment: The Sodium Chloride Equivalent ( E E E -Value) Method
The E E E -value is the weight of sodium chloride that produces an identical osmotic effect to 1 g 1\text{ g} 1 g of the active medication. Pharmacists use a 3-step calculation to compound isotonic ophthalmic and parenteral solutions:
Calculate total NaCl required for isotonicity ( 0.9 % w/v = 0.009 g/mL 0.9\%\text{ w/v} = 0.009\text{ g/mL} 0.9% w/v = 0.009 g/mL ): Target NaCl (g) = 0.009 × Batch Volume (mL) \text{Target NaCl (g)} = 0.009 \times \text{Batch Volume (mL)} Target NaCl (g) = 0.009 × Batch Volume (mL)
Calculate the tonic contribution of the drug : Drug Contribution (g NaCl) = Weight of Drug (g) × E \text{Drug Contribution (g NaCl)} = \text{Weight of Drug (g)} \times E Drug Contribution (g NaCl) = Weight of Drug (g) × E
Calculate the required mass of NaCl to add : NaCl to Add (g) = Target NaCl (g) − Drug Contribution (g) \text{NaCl to Add (g)} = \text{Target NaCl (g)} - \text{Drug Contribution (g)} NaCl to Add (g) = Target NaCl (g) − Drug Contribution (g)
Renal Clearance Assessment: Cockcroft-Gault Posology in Canadian SI Units
While clinical biochemistry reports in Canada frequently provide estimated glomerular filtration rate (eGFR) via the CKD-EPI equation for disease classification, many product monographs base renal dose adjustments on Cockcroft-Gault creatinine clearance (CrCl) , notably the direct oral anticoagulants (DOACs), many antimicrobials, and gabapentinoids. Other monographs and guidelines use eGFR instead (for example, SGLT2 inhibitor and metformin thresholds), so read which measure the label or the exam stem specifies.
The Cockcroft-Gault Equations
In Canadian hospital and ambulatory practice, serum creatinine ( S cr S_{\text{cr}} S cr ) is reported in SI units ( μ mol/L \mu\text{mol/L} μ mol/L ) :
CrCl male ( mL/min ) = ( 140 − Age ) × Weight (kg) × 1.2 S cr ( μ mol/L ) CrCl female = 0.85 × CrCl male \text{CrCl}_{\text{male}}\ (\text{mL/min}) = \frac{(140 - \text{Age}) \times \text{Weight (kg)} \times 1.2}{S_{\text{cr}}\ (\mu\text{mol/L})} \qquad \text{CrCl}_{\text{female}} = 0.85 \times \text{CrCl}_{\text{male}} CrCl male ( mL/min ) = S cr ( μ mol/L ) ( 140 − Age ) × Weight (kg) × 1.2 CrCl female = 0.85 × CrCl male
Important
This is the version printed on the PEBC formula sheet (constant 1.2 , actual body weight). Many Canadian references use 1.23 instead, which gives results about 2.5% higher. On the exam, use the formula-sheet constant 1.2 and the actual body weight unless the stem tells you to use another weight descriptor. In PEBC's published sample items, a CrCl question uses actual weight, while an aminoglycoside dosing question specifies adjusted body weight.
When using conventional units ( S cr S_{\text{cr}} S cr in mg/dL \text{mg/dL} mg/dL ):
CrCl (mL/min) = ( 140 − Age ) × Weight (kg) 72 × S cr ( mg/dL ) × [ 0.85 if female ] \text{CrCl (mL/min)} = \frac{(140 - \text{Age}) \times \text{Weight (kg)}}{72 \times S_{\text{cr}}\ (\text{mg/dL})} \times [0.85 \text{ if female}] CrCl (mL/min) = 72 × S cr ( mg/dL ) ( 140 − Age ) × Weight (kg) × [ 0.85 if female ]
Conversion Factor : S cr ( μ mol/L ) = S cr ( mg/dL ) × 88.4 S_{\text{cr}}\ (\mu\text{mol/L}) = S_{\text{cr}}\ (\text{mg/dL}) \times 88.4 S cr ( μ mol/L ) = S cr ( mg/dL ) × 88.4 .
Weight Selection Rules in Cockcroft-Gault Calculations
In clinical practice, many hospital protocols pick the weight descriptor with the following algorithm. On the exam, follow the stem: use actual body weight by default, and use IBW or AdjBW only when the stem asks for it or gives you that value:
Calculate Ideal Body Weight (IBW) via Devine Formula : IBW male = 50 kg + 2.3 × ( Height in inches − 60 ) \text{IBW}_{\text{male}} = 50\text{ kg} + 2.3 \times (\text{Height in inches} - 60) IBW male = 50 kg + 2.3 × ( Height in inches − 60 ) IBW female = 45.5 kg + 2.3 × ( Height in inches − 60 ) \text{IBW}_{\text{female}} = 45.5\text{ kg} + 2.3 \times (\text{Height in inches} - 60) IBW female = 45.5 kg + 2.3 × ( Height in inches − 60 )
Apply the Weight Selection Algorithm :
Underweight (Actual Weight < IBW) : Use Actual Body Weight (ABW) . Using IBW would falsely overestimate clearance in cachectic or frail individuals.
Normal Weight (Actual Weight 100 % 100\% 100% to 120 % 120\% 120% of IBW) : Use IBW . Adipose tissue contributes negligibly to creatinine generation.
Obese (Actual Weight > 120 % 120\% 120% of IBW) : Use Adjusted Body Weight (AdjBW) : AdjBW = IBW + 0.4 × ( ABW − IBW ) \text{AdjBW} = \text{IBW} + 0.4 \times (\text{ABW} - \text{IBW}) AdjBW = IBW + 0.4 × ( ABW − IBW ) Patient Weight Assessment:
- ├── Actual Weight < IBW ──> Use Actual Body Weight (ABW)
- ├── Actual Weight = 100% to 120% IBW ──> Use Ideal Body Weight (IBW)
- └── Actual Weight > 120% IBW (Obese) ──> Use Adjusted Body Weight (AdjBW)
- Worked Clinical Case: Renal Drug Dosing in Obesity
Case : A 70-year-old female patient (height: 165 cm = 65 inches 165\text{ cm} = 65\text{ inches} 165 cm = 65 inches ; actual weight: 92 kg 92\text{ kg} 92 kg ) is being evaluated for rivaroxaban therapy for non-valvular atrial fibrillation. Her laboratory panel shows S cr = 110 μ mol/L S_{\text{cr}} = 110\ \mu\text{mol/L} S cr = 110 μ mol/L .
Calculate IBW : IBW = 45.5 + 2.3 × ( 65 − 60 ) = 45.5 + 11.5 = 57.0 kg \text{IBW} = 45.5 + 2.3 \times (65 - 60) = 45.5 + 11.5 = 57.0\text{ kg} IBW = 45.5 + 2.3 × ( 65 − 60 ) = 45.5 + 11.5 = 57.0 kg
Evaluate Weight Ratio : ABW IBW = 92 kg 57 kg = 1.61 = 161 % ( > 120 % ⟹ obese ) \frac{\text{ABW}}{\text{IBW}} = \frac{92\text{ kg}}{57\text{ kg}} = 1.61 = 161\% \quad (>120\% \implies \text{obese}) IBW ABW = 57 kg 92 kg = 1.61 = 161% ( > 120% ⟹ obese )
Calculate Adjusted Body Weight : AdjBW = 57.0 + 0.4 × ( 92 − 57.0 ) = 57.0 + 0.4 × ( 35.0 ) = 57.0 + 14.0 = 71.0 kg \text{AdjBW} = 57.0 + 0.4 \times (92 - 57.0) = 57.0 + 0.4 \times (35.0) = 57.0 + 14.0 = 71.0\text{ kg} AdjBW = 57.0 + 0.4 × ( 92 − 57.0 ) = 57.0 + 0.4 × ( 35.0 ) = 57.0 + 14.0 = 71.0 kg
Calculate CrCl in SI Units : CrCl = ( 140 − 70 ) × 71.0 kg × 1.2 110 μ mol/L × 0.85 = 5 , 964 110 × 0.85 ≈ 46.1 mL/min \text{CrCl} = \frac{(140 - 70) \times 71.0\text{ kg} \times 1.2}{110\ \mu\text{mol/L}} \times 0.85 = \frac{5,964}{110} \times 0.85 \approx 46.1\text{ mL/min} CrCl = 110 μ mol/L ( 140 − 70 ) × 71.0 kg × 1.2 × 0.85 = 110 5 , 964 × 0.85 ≈ 46.1 mL/min
Clinical Dose Implication : For rivaroxaban in non-valvular atrial fibrillation, Thrombosis Canada guidelines state: standard dose is 20 mg 20\text{ mg} 20 mg once daily if CrCl ≥ 50 mL/min \text{CrCl} \ge 50\text{ mL/min} CrCl ≥ 50 mL/min ; reduce to 15 mg 15\text{ mg} 15 mg once daily if CrCl \text{CrCl} CrCl is 30 – 49 mL/min 30\text{--}49\text{ mL/min} 30 – 49 mL/min . Because her calculated CrCl \text{CrCl} CrCl is about 46 mL/min 46\text{ mL/min} 46 mL/min , she requires the adjusted dose of 15 mg 15\text{ mg} 15 mg once daily . With actual body weight ( 92 kg 92\text{ kg} 92 kg ), the estimate would be about 60 mL/min 60\text{ mL/min} 60 mL/min and would point to the full dose, so the weight choice changes the decision here.